Judge blocks Colorado's first-of-its-kind price cap on Amgen's Enbrel

A federal judge blocked Colorado from implementing a cap on the price of Amgen’s Enbrel, stopping what would have been the first state-level limit of its kind. The ruling preserves Enbrel’s pricing power at the state level while keeping regulatory overhang risk elevated for branded biologics. Outcome is a near-term positive for Amgen, but investors may remain cautious about the broader political/regulatory direction of drug pricing.

Analysis

A federal judge blocked Colorado from implementing a cap on the price of Amgen’s Enbrel, stopping what would have been the first state-level limit of its kind. The ruling preserves Enbrel’s pricing power at the state level while keeping regulatory overhang risk elevated for branded biologics. Outcome is a near-term positive for Amgen, but investors may remain cautious about the broader political/regulatory direction of drug pricing.